摘要
自身免疫性皮肤病是一组临床表现多样、发生机制复杂的疾病。糖皮质激素和免疫抑制剂等作为自身免疫性皮肤病传统的治疗方式往往给患者带来较多的不良反应,且部分患者治疗效果不理想。而生物制剂具有较高的特异性,只针对靶向分子,在增加疗效的同时,也减少了因广泛免疫抑制而所引起的不良反应。随着生物制剂研发和运用的迅速发展,为临床上自身免疫性皮肤病的治疗带来了新选择。本文就生物制剂在自身免疫性皮肤病临床治疗中的新进展进行综述。
Autoimmune cutaneous disease is a heterogeneous and complicated group of cutaneous diseases.however,traditional treatments for autoimmune cutaneous diseases,such as glucosticoid and immunosuppressor,are not responded well for patients,who often need to undertake the side-effect of the drug.Biological agents are with high specificity,which means they can reduce the side-effect caused by extensive immunosuppression through aiming at Targeted Molecules.With the rapid development of biological agents,there are new options for the treatment of Autoimmune cutaneous diseases.In this paper,the new progress of biologies in the treatment of autoimmune skin diseases is reviewed.
作者
何杏兰
史雅倩
肖嵘
HE Xinglan;Shi Yaqian;XIA Rong(Department of dermatology,Second Xiangya Hospital,Central South Universily,410011,China)
出处
《皮肤科学通报》
2020年第5期540-548,M0008,M0009,共11页
Dermatology Bulletin
关键词
自身免疫性皮肤病
生物制剂
治疗
Autoimmune cutaneous diseases
Biological Agents
Treatment
